HOUSTON, March 20, 2020 /PRNewswire/ -- Soliton,
Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), today announced
that Dr. Elizabeth Tanzi, lead
investigator on Soliton's pivotal cellulite trial is evaluating
alternative presentation opportunities after the American Academy
of Dermatology (AAD) canceled its annual meeting due to the current
coronavirus (COVID-19) outbreak.
Soliton announced March 3, 2020,
the results from its pivotal cellulite trial had been accepted for
a podium presentation by Scientific Advisory Board member and
leading dermatologist, Dr. Tanzi at the AAD 2020 Annual Meeting. As
the medical meeting was cancelled due to COVID-19 concerns, Dr.
Tanzi is now exploring alternative presentation options to the
scientific community.
"The AAD Annual Meeting is one of the most prestigious
dermatology conferences that grants physicians across the globe
access to the latest and most innovative technologies in the
dermatology industry. We believe that the opportunity to present
clinical results at such a venue bestows a specific validation that
industry physicians prefer and have come to expect," stated
Christopher Capelli, MD, founder,
President and CEO of Soliton. "Given the current uncertainty
surrounding COVID-19, Dr. Tanzi is evaluating alternative avenues
to present our pivotal cellulite results. Once identified, we will
immediately communicate that to our shareholders. We appreciate
everyone's patience during this challenging time for our
country."
Join our more than 200K fans here
to follow the Company: https://soly-investors.com
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product will use rapid
pulses of acoustic shockwaves as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse ("RAP") device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal methods.
Soliton is investigating potential additional capabilities of the
RAP technology in clinical and preclinical testing, including the
potential to improve the appearance of cellulite by creating
mechanical stress at the cellular level and inducing significant
collagen growth and the potential to treat keloid and hypertrophic
scars by targeting the stiffened environment in the intracellular
matrix.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability to announce
results from the cellulite pivotal study. These statements
relate to future events, future expectations, plans and prospects.
Although Soliton believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
Soliton has attempted to identify forward-looking statements by
terminology including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
in our SEC filings, including under the heading "Item 1A. Risk
Factors" in the Form 10-K for year ended December 31, 2019 we filed with the SEC and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lead-investigator-evaluates-next-step-for-soliton-pivotal-cellulite-clinical-data-301027230.html
SOURCE Soliton, Inc.